Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib of Cyclophosphamide, Pomalidomide, Dexamethasone and Daratumumab (CPD-DARA) in Patients With Relapsed/Refractory Multiple Myeloma. (The CPD-DARA Study)

NCT04667663 is registered in ClinicalTrials.gov with Cancer Trials Ireland as lead sponsor.

NCT NCT04667663
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04667663 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib of Cyclophosphamide, Pomalidomide, Dexamethasone and Daratumumab (CPD-DARA) in Patients With Relapsed/Refractory Multiple Myeloma. (The CPD-DARA Study)
Lead sponsor
Cancer Trials Ireland
Phase
Phase 1
Overall status
Active, not recruiting
Start date
December 8, 2021
Completion date
April 30, 2026
Enrollment
16 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma